Document is current
Any future updates will be listed below
-
Authors
Solana, Elisabeth
Martinez-Heras, Eloy
Montal, Victor
Vilaplana, Eduard
Lopez-Soley, Elisabet
Radua, Joaquim
Sola-Valls, Nuria
Montejo, Carmen
Blanco, Yolanda
Pulido-Valdeolivas, Irene
Sepúlveda, Maria
Andorra, Magi
Berenguer, Joan
Villoslada, Pablo
Martinez-Lapiscina, E. H.
Prados, Ferran
Saiz, Albert
Fortea, Juan
Llufriu, Sara
-
Funding
Funding for this research was provided by:
Ayudas Merck de Investigación
Proyecto Societat Catalana Neurologia
Proyecto de Investigación en Salud (PI15/00587; PI15/00061; PI18/01030; PI14/01126; PI17/01019; JR16/00006; MV17/00021; PI17/01228; RD16/0015/0003; FI19/00111; CPII19/0000; PI19/00394, PI15/00587; PI15/00061; PI18/01030; PI14/01126; PI17/01019; JR16/00006; MV17/00021; PI17/01228; RD16/0015/0003; FI19/00111; CPII19/0000; PI19/00394, PI15/00587; PI15/00061; PI18/01030; PI14/01126; PI17/01019; JR16/00006; MV17/00021; PI17/01228; RD16/0015/0003; FI19/00111; CPII19/0000; PI19/00394, PI15/00587; PI15/00061; PI18/01030; PI14/01126; PI17/01019; JR16/00006; MV17/00021; PI17/01228; RD16/0015/0003; FI19/00111; CPII19/0000; PI19/00394, PI15/00587; PI15/00061; PI18/01030; PI14/01126; PI17/01019; JR16/00006; MV17/00021; PI17/01228; RD16/0015/0003; FI19/00111; CPII19/0000; PI19/00394, PI15/00587; PI15/00061; PI18/01030; PI14/01126; PI17/01019; JR16/00006; MV17/00021; PI17/01228; RD16/0015/0003; FI19/00111; CPII19/0000; PI19/00394, PI15/00587; PI15/00061; PI18/01030; PI14/01126; PI17/01019; JR16/00006; MV17/00021; PI17/01228; RD16/0015/0003; FI19/00111; CPII19/0000; PI19/00394, PI15/00587; PI15/00061; PI18/01030; PI14/01126; PI17/01019; JR16/00006; MV17/00021; PI17/01228; RD16/0015/0003; FI19/00111; CPII19/0000; PI19/00394, PI15/00587; PI15/00061; PI18/01030; PI14/01126; PI17/01019; JR16/00006; MV17/00021; PI17/01228; RD16/0015/0003; FI19/00111; CPII19/0000; PI19/00394, PI15/00587; PI15/00061; PI18/01030; PI14/01126; PI17/01019; JR16/00006; MV17/00021; PI17/01228; RD16/0015/0003; FI19/00111; CPII19/0000; PI19/00394, PI15/00587; PI15/00061; PI18/01030; PI14/01126; PI17/01019; JR16/00006; MV17/00021; PI17/01228; RD16/0015/0003; FI19/00111; CPII19/0000; PI19/00394, PI15/00587; PI15/00061; PI18/01030; PI14/01126; PI17/01019; JR16/00006; MV17/00021; PI17/01228; RD16/0015/0003; FI19/00111; CPII19/0000; PI19/00394, PI15/00587; PI15/00061; PI18/01030; PI14/01126; PI17/01019; JR16/00006; MV17/00021; PI17/01228; RD16/0015/0003; FI19/00111; CPII19/0000; PI19/00394, PI15/00587; PI15/00061; PI18/01030; PI14/01126; PI17/01019; JR16/00006; MV17/00021; PI17/01228; RD16/0015/0003; FI19/00111; CPII19/0000; PI19/00394, PI15/00587; PI15/00061; PI18/01030; PI14/01126; PI17/01019; JR16/00006; MV17/00021; PI17/01228; RD16/0015/0003; FI19/00111; CPII19/0000; PI19/00394)
Red Española de Esclerosis Múltiple (RD16/0015/0002, RD16/0015/0003, RD12/0032/0002, RD12/0060/01-02, RD16/0015/0002, RD16/0015/0003, RD12/0032/0002, RD12/0060/01-02, RD16/0015/0002, RD16/0015/0003, RD12/0032/0002, RD12/0060/01-02, RD16/0015/0002, RD16/0015/0003, RD12/0032/0002, RD12/0060/01-02, RD16/0015/0002, RD16/0015/0003, RD12/0032/0002, RD12/0060/01-02, RD16/0015/0002, RD16/0015/0003, RD12/0032/0002, RD12/0060/01-02, RD16/0015/0002, RD16/0015/0003, RD12/0032/0002, RD12/0060/01-02, RD16/0015/0002, RD16/0015/0003, RD12/0032/0002, RD12/0060/01-02, RD16/0015/0002, RD16/0015/0003, RD12/0032/0002, RD12/0060/01-02, RD16/0015/0002, RD16/0015/0003, RD12/0032/0002, RD12/0060/01-02)
TEVA Spain
CIBERNED program
National Institutes of Health (1R01AG056850–01A1; R21AG056974 and R01AG061566, 1R01AG056850–01A1; R21AG056974 and R01AG061566, 1R01AG056850–01A1; R21AG056974 and R01AG061566)
Fundació la Marató de TV3 (20142030; 20141210, 20142030; 20141210, 20142030; 20141210, 20142030; 20141210, 20142030; 20141210, 20142030; 20141210, 20142030; 20141210)
Fundació Catalana Síndrome de Down
Fundació Víctor Grífols i Lucas
Generalitat de Catalunya (SLT006/17/00119, SLT006/17/00119, SLT006/17/00119)
University of Barcelona
Hospital Clinic Emili Letang
MS Innovation GMSI
- License Information
-
More Information
Article History
Received: 9 April 2021
Accepted: 3 August 2021
First Online: 19 August 2021
Competing interests
: E.M.-H., V.M., E.V., J.R., C.M., J.B. and F.P. have nothing to disclose. E.S and E.L.-S received travel reimbursement from Sanofi; N.S.-V. received compensation for consulting services and speaker honoraria from Genzyme-Sanofi, Novartis, Roche and Almirall; Y.B. received speaking honoraria from Biogen, Novartis and Genzyme; I.P.-V. received travel reimbursement from Roche and Genzyme, and she holds stock options in Aura Innovative Robotics. Currently, she is an employee at UCB Pharma, her contribution to this work is associated with her previous work at IDIBAPS; M.S. received speaker honoraria from Genzyme, Novartis and Biogen; M.A. holds equity shares of Bionure, S.L. and Goodgut S.L. and stock options of Attune Neurosciences Inc. He is currently an employee of Roche, although his contribution to this work is associated with his previous work at IDIBAPS; E.H.M.-L. received travel support for international and national meetings from Roche and Sanofi-Genzyme, and honoraria for consultancies from Novartis, Roche and Sanofi. She is currently employed by the European Medicines Agency (Human Medicines) since 16 April 2019. This article is related with her activity under Hospital Clinic of Barcelona/IDIBAPS affiliation and consequently, as external activity, it does not represent the views of the Agency or its Committees. She is a member of the International Multiple Sclerosis Visual System (IMSVISUAL) Consortium; A.S. received compensation for consulting services and speaker honoraria from Bayer-Schering, Merck-Serono, Biogen-Idec, Sanofi-Aventis, TEVA, Novartis and Roche; J.F. has received compensation for consultancies to Novartis, Lündbeck and AC Immune; S.L. received compensation for consulting services and speaker honoraria from Biogen Idec, Novartis, TEVA, Genzyme, Sanofi and Merck.
